Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/affordable-medicine-10333/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/affordable-medicine-10333/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/affordable-medicine-10333/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/affordable-medicine-10333/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-trace').style.display = (document.getElementById('cakeErr67f2c1e55c276-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f2c1e55c276-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-code').style.display = (document.getElementById('cakeErr67f2c1e55c276-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-context').style.display = (document.getElementById('cakeErr67f2c1e55c276-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f2c1e55c276-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f2c1e55c276-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 10222,
		&#039;title&#039; =&gt; &#039;Affordable medicine&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The Business Standard
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;
&lt;br /&gt;
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;affordable-medicine-10333&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 10333,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 10222,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Affordable medicine&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard


&amp;nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p&gt;-The Business Standard&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;&lt;br /&gt;However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 10222,
	&#039;title&#039; =&gt; &#039;Affordable medicine&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The Business Standard
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;
&lt;br /&gt;
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;affordable-medicine-10333&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 10333,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 10222
$metaTitle = &#039;LATEST NEWS UPDATES | Affordable medicine&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;
-The Business Standard


&amp;nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...&#039;
$disp = &#039;&lt;p&gt;-The Business Standard&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;&lt;br /&gt;However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/affordable-medicine-10333.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Affordable medicine | Im4change.org</title>
    <meta name="description" content="
-The Business Standard


&nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Affordable medicine</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p>-The Business Standard</p><p>&nbsp;</p><div align="justify">It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br /><br />However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-trace').style.display = (document.getElementById('cakeErr67f2c1e55c276-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f2c1e55c276-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-code').style.display = (document.getElementById('cakeErr67f2c1e55c276-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-context').style.display = (document.getElementById('cakeErr67f2c1e55c276-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f2c1e55c276-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f2c1e55c276-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 10222,
		&#039;title&#039; =&gt; &#039;Affordable medicine&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The Business Standard
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;
&lt;br /&gt;
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;affordable-medicine-10333&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 10333,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 10222,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Affordable medicine&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard


&amp;nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p&gt;-The Business Standard&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;&lt;br /&gt;However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 10222,
	&#039;title&#039; =&gt; &#039;Affordable medicine&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The Business Standard
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;
&lt;br /&gt;
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;affordable-medicine-10333&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 10333,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 10222
$metaTitle = &#039;LATEST NEWS UPDATES | Affordable medicine&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;
-The Business Standard


&amp;nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...&#039;
$disp = &#039;&lt;p&gt;-The Business Standard&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;&lt;br /&gt;However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/affordable-medicine-10333.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Affordable medicine | Im4change.org</title>
    <meta name="description" content="
-The Business Standard


&nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Affordable medicine</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p>-The Business Standard</p><p>&nbsp;</p><div align="justify">It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br /><br />However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-trace').style.display = (document.getElementById('cakeErr67f2c1e55c276-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f2c1e55c276-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-code').style.display = (document.getElementById('cakeErr67f2c1e55c276-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2c1e55c276-context').style.display = (document.getElementById('cakeErr67f2c1e55c276-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f2c1e55c276-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f2c1e55c276-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 10222,
		&#039;title&#039; =&gt; &#039;Affordable medicine&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The Business Standard
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;
&lt;br /&gt;
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;affordable-medicine-10333&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 10333,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 10222,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Affordable medicine&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard


&amp;nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p&gt;-The Business Standard&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;&lt;br /&gt;However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 10222,
	&#039;title&#039; =&gt; &#039;Affordable medicine&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p&gt;
-The Business Standard
&lt;/p&gt;
&lt;p&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;div align=&quot;justify&quot;&gt;
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;
&lt;br /&gt;
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;affordable-medicine-10333&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 10333,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 10222
$metaTitle = &#039;LATEST NEWS UPDATES | Affordable medicine&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;
-The Business Standard


&amp;nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...&#039;
$disp = &#039;&lt;p&gt;-The Business Standard&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div align=&quot;justify&quot;&gt;It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&amp;rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &amp;ldquo;hypothesis&amp;rdquo; that &amp;ldquo;foreign ownership would change pricing&amp;rdquo;. Unfortunately, this is more than a &amp;ldquo;hypothesis&amp;rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&amp;rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.&lt;br /&gt;&lt;br /&gt;However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &amp;mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &amp;mdash; which is why they need to win the trust of Indian policy makers.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/affordable-medicine-10333.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Affordable medicine | Im4change.org</title>
    <meta name="description" content="
-The Business Standard


&nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Affordable medicine</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p>-The Business Standard</p><p>&nbsp;</p><div align="justify">It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br /><br />However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 10222,
		'title' => 'Affordable medicine',
		'subheading' => '',
		'description' => '<p>
-The Business Standard
</p>
<p>
&nbsp;
</p>
<div align="justify">
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br />
<br />
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.
</div>',
		'credit_writer' => 'The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'affordable-medicine-10333',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 10333,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 10222,
	'metaTitle' => 'LATEST NEWS UPDATES | Affordable medicine',
	'metaKeywords' => 'Health',
	'metaDesc' => '
-The Business Standard


&nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...',
	'disp' => '<p>-The Business Standard</p><p>&nbsp;</p><div align="justify">It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br /><br />However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 10222,
	'title' => 'Affordable medicine',
	'subheading' => '',
	'description' => '<p>
-The Business Standard
</p>
<p>
&nbsp;
</p>
<div align="justify">
It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br />
<br />
However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.
</div>',
	'credit_writer' => 'The Business Standard, 30 September, 2011, http://www.business-standard.com/india/news/affordable-medicine/450897/',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'affordable-medicine-10333',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 10333,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 10222
$metaTitle = 'LATEST NEWS UPDATES | Affordable medicine'
$metaKeywords = 'Health'
$metaDesc = '
-The Business Standard


&nbsp;


It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only...'
$disp = '<p>-The Business Standard</p><p>&nbsp;</p><div align="justify">It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries&rsquo; demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the &ldquo;hypothesis&rdquo; that &ldquo;foreign ownership would change pricing&rdquo;. Unfortunately, this is more than a &ldquo;hypothesis&rdquo;. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India&rsquo;s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame.<br /><br />However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&amp;D spending but recent statistics point to low MNC investment in India in manufacturing and research &mdash; hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score &mdash; which is why they need to win the trust of Indian policy makers.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Affordable medicine

-The Business Standard   It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries’ demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for wider powers for the Competition Commission of India to ensure that competition does not suffer as a result of foreign takeovers. Lobbying on behalf of pharma MNCs, Andrew Witty, CEO of GlaxoSmithKline Plc, told a Mumbai audience that foreign ownership should not be viewed as a barrier to affordable medicine. He refused to buy the “hypothesis” that “foreign ownership would change pricing”. Unfortunately, this is more than a “hypothesis”. For a large number of products, drug MNCs have been forced to bring down prices owing to competition from developing country firms, which has served the interests of weaker sections of society the world over. The health ministry is worried that too many leading Indian companies falling into foreign hands will hinder the availability of cheap medicines, which will be inimical to public health. The counter-argument is that should the need arise the government can always resort to compulsory licensing to make available an essential medicine. Besides, if willing manufacturers are difficult to find, the several dormant pharmaceutical firms in the public sector can easily be revived to manufacture medicines. In fact, India’s inability to cover all its children under essential immunisation programmes even as public-sector vaccine manufacturers remain dormant is a crying shame. However, large Indian manufacturers have been lobbying for a change on a longer-term issue. Indian generics today pose the biggest challenge to drug MNCs and takeover of leading Indian players will put an end to patent challenging, which lies at the heart of the process of creating space for generics, particularly when MNCs are using ingenuity and influence to take forward their agenda. Much of the innovation in low-cost drugs is driven by domestic companies. So if the good ones no longer remain domestic, then who will do the job? It is also argued that instead of feeding the domestic market with low-cost medicines, MNCs with their Indian acquisitions will be more interested in exports. Also, they will try to keep other Indian manufacturers out of third countries. FDI is commonly associated with innovation and higher R&D spending but recent statistics point to low MNC investment in India in manufacturing and research — hence the plea to restrict automaticity to greenfield investment to bring in new technology for local manufacture of active pharmaceutical ingredients from the basic stage, to indigenous manufacture of patented medicines, and to fund discovery research in India. But investment in existing firms should not be allowed automatically. This is an eminently sensible view. However, if drug MNCs believe this view is unfair, then the onus is on them to convince public opinion and policy makers in India that an MNC takeover will not result in higher prices for drugs or restrict research in low-cost drugs. The track record of western MNCs does not inspire confidence on this score — which is why they need to win the trust of Indian policy makers.